8-K filing — Prelude Therapeutics Inc (PRLD)
Filed: 2026-08-11 AccNo: 0001193125-26-343469 Size: 412 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
Prelude Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 11, 2026, 7:18 PM
- Checked
- Aug 11, 2026, 7:18 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Prelude Therapeutics Q2 EPS $(0.14) Beats $(0.20) Estimate, Sales $5.704M
Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.20) by 30 percent. This is a 65.85 percent increase over losses of $(0.41) per share
Read original at benzingaHC Wainwright & Co. Reiterates Buy on Prelude Therapeutics, Maintains $8 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $8 price target.
Read original at benzinga